Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359313 | 0.83 | CFTR (0.44) | SCN10ACFTRPIK3CAPIK3CDPIK3CB | |
| SCHEMBL30544220 | 0.79 | NQO2 (0.48) | ADCY10NQO2ALDH1A1GAAKMT2A | |
| SCHEMBL11023739 | 0.79 | NQO2 (0.48) | ADCY10NQO2ALDH1A1GAAKMT2A | |
| SCHEMBL30516416 | 0.78 | LMNA (0.41) | NQO2S1PR2ALDH1A1GAA | |
| SCHEMBL536122 | 0.78 | TDP1 (0.46) | NQO2S1PR2ALDH1A1MEN1KMT2A | |
| SCHEMBL31555817 | 0.76 | SCN10A (0.43) | SCN10ACFTRPIK3CAPIK3CDPIK3CB | |
| SCHEMBL30494923 | 0.74 | CFTR (0.44) | SCN10ACFTRPIK3CAPIK3CDPIK3CB | |
| SCHEMBL21367897 | 0.74 | CFTR (0.44) | SCN10ACFTRPIK3CAPIK3CDPIK3CB | |
| SCHEMBL25225311 | 0.73 | ALPL (0.39) | SCN10ACFTRPIK3CAPIK3CDPIK3CB | |
| SCHEMBL30352714 | 0.73 | ALPL (0.39) | SCN10ACFTRPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250042897-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2024233847-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430029-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | SCN10A 3013/4885CFTR 2356/4885PIK3CA 3198/4885 |
| US-20250042897-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | SCN10A 2734/4885CFTR 2148/4885PIK3CA 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.